Can zapping cancer spots delay lung cancer progression?
NCT ID NCT05429320
First seen Feb 02, 2026 · Last updated Jun 20, 2026 · Updated 18 times
Summary
This study tested whether a procedure called local ablative therapy (LAT) can help control metastatic non-small cell lung cancer (NSCLC) when a blood test shows signs of remaining cancer (minimal residual disease, or MRD). 37 patients with stage IV NSCLC received LAT to all visible cancer sites. The goal was to see if LAT could reduce MRD levels and delay cancer growth compared to continuing standard therapy alone.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MINIMAL RESIDUAL DISEASE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
BAPTIST ALLIANCE - MCI (Data collection only)
Miami, Florida, 33143, United States
-
Hartford Healthcare ALLIANCE (Data collection only)
Hartford, Connecticut, 06102, United States
-
Memorial Sloan Kettering Bergen (Limited Protocol Activities)
Montvale, New Jersey, 07645, United States
-
Memorial Sloan Kettering Cancer Center (All Protocol Activities)
New York, New York, 10065, United States
-
Memorial Sloan Kettering Monmouth (Limited Protocol Activities)
Middletown, New Jersey, 07748, United States
-
Memorial Sloan Kettering Nassau (Limited Protocol Activities)
Uniondale, New York, 11553, United States
-
Memorial Sloan Kettering Suffolk-Commack (Limited Protocol Activities)
Commack, New York, 11725, United States
-
Memorial Sloan Kettering Westchester (Limited Protocol Activities)
Harrison, New York, 10604, United States
-
Memorial Sloan Kettering at Basking Ridge (Limited Protocol Activities)
Basking Ridge, New Jersey, 07920, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
local ablative therapy (LAT) - a procedure that destroys cancer cells using heat, cold, or radiation
What this could lead to
If successful, this approach could offer a way to delay cancer progression and extend the time before patients need stronger systemic treatments.
What could go wrong
This is a small, early-phase study (37 participants) with no control group in Part I. The treatment may not reduce MRD levels or improve survival, and side effects from ablation are possible.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.